8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 22, 2025)

Filed January 22, 2025For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report on January 22, 2025, announcing its financial results for the fourth quarter and full year 2024. The report primarily references a press release (Exhibit 99.1) that details these results. Investors should note that Abbott utilizes non-GAAP financial measures to present its performance, adjusting for items such as acquisition and divestiture expenses, restructuring costs, fair value adjustments, impairment charges, regulatory costs, tax-related adjustments, and intangible amortization. The company states that these non-GAAP measures offer better insight into ongoing business performance as assessed by management, but investors are cautioned to consider them alongside GAAP measures.

Key Highlights

  • 1Abbott Laboratories reported its Q4 and full-year 2024 financial results on January 22, 2025.
  • 2The results are detailed in a press release furnished as Exhibit 99.1.
  • 3The company employs non-GAAP financial measures for performance reporting.
  • 4Non-GAAP adjustments include expenses related to acquisitions, divestitures, restructuring, and impairments.
  • 5Other adjustments comprise fair value changes, regulatory costs, tax benefits/expenses, and intangible amortization.
  • 6Abbott's management believes non-GAAP measures provide a clearer view of ongoing operational performance.
  • 7Investors are advised to review non-GAAP measures in conjunction with GAAP-compliant financial data.

Frequently Asked Questions

This 8-K filing announces Abbott Laboratories' financial results for the fourth quarter and full year of 2024, primarily referencing a press release containing these details.

Abbott uses non-GAAP financial measures to exclude certain items that management considers unusual or unpredictable, such as acquisition/divestiture costs, restructuring expenses, and intangible amortization. The company believes these measures provide a better understanding of its ongoing business performance.

Abbott cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). This means investors should look at both GAAP and non-GAAP figures for a complete picture.

The detailed financial results are provided in the press release issued by Abbott on January 22, 2025, which is furnished as Exhibit 99.1 to this 8-K filing.